Medpace Holdings, Inc. (MEDP) SEC Filings & Earnings Calls

Litigation risk from securities class action and derivative lawsuits

“On April 6, 2026, Jan Durbin filed a class action complaint ... alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ... related to the Company’s book-to-bill ratio.” · word for word

Customer concentration risk with related parties

“Revenue from CinRx declined from $10.4M to $2.3M QoQ; from $37.2M to $11.9M YTD.”

No share repurchases in Q3 2026 despite authorization

“There were no share repurchases in the third quarter of 2026.” · word for word

Insider selling by founder/CEO

“August J. Troendle ("Mr. Troendle") has sold shares of common stock in open market transactions executed pursuant to limit orders between August 10, 2026 and September 25, 2026 as follows: ...” · word for word

Customer concentration risk

“Cancellation provisions in our contracts allow our customers to terminate a contract either immediately or according to advance notice terms specified within the applicable contract, which is typically 30 days.” · word for word

Foreign exchange risk

“The Euro represents the largest foreign currency denomination of our contractual and operational exposure.” · word for word

Direct costs increased 19.5% YoY, slightly outpacing revenue growth of 17.2%, potentially pressuring gross margin

“total direct costs were $505.7 million, compared to total direct costs of $423.3 million in the second quarter of 2025” · word for word

Customer concentration risk

“small- and mid-sized biopharmaceutical companies”

Cancellation risk

“majority of our customers can terminate our contracts without cause upon 30 days’ notice” · word for word

President departure creates leadership transition risk, though CEO reassumes role.

“Jesse Geiger notified the Company of his intent to resign as President and that he will retire from the Company effective May 31, 2026.” · word for word

Related Party Concentration

“The Company recognized total revenue from CinRx of $45.3 million...The Company recognized total revenue from LIB of $7.9 million...Operating lease cost recognized for the year ended December 31, 2025 was $2.7 million...$5.7 million...$2.5 million...$0.8 million...The Company incurred travel expenses of $2.1 million.” · word for word

CEO Control

“August J. Troendle, as the sole manager and controlling unit holder of Medpace Investors, LLC...has sole voting and investment control with respect to these shares.” · word for word

Governance Risk

“Stockholder proposal: 'Medpace experienced weak net book-to-bill ratios in Q4 2024 and Q1 2025...The Schall Law Firm was investigating Medpace for potential securities law violations...There were reports of "heavy" insider selling of Medpace stock, including by the CEO and other executives.'”

Key person / CEO concentration risk

“August J. Troendle, our Chief Executive Officer and founder, controls approximately 19.0% of the outstanding shares of our common stock.” · word for word

Tax rate volatility

“Our effective income tax rate may fluctuate, which may adversely affect our operations, earnings and earnings per share.” · word for word

Net income margin compression due to higher direct costs.

“Net income margin decreased from 21.8% to 19.1%”